PSMA-ADC-1301
- Generic Name
- PSMA-ADC-1301
An Open-label Extension Study of PSMA ADC 2301 in mCRPC
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- Progenics Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02020135
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Heinrich Elinzano, MD
- Target Recruit Count
- 6
- Registration Number
- NCT01856933
- Locations
- 🇺🇸
UT Southwestern, Dallas, Texas, United States
🇺🇸Rhode Island Hospital, Providence, Rhode Island, United States
A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- Progenics Pharmaceuticals, Inc.
- Target Recruit Count
- 119
- Registration Number
- NCT01695044
Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Progenics Pharmaceuticals, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01414283
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Progenics Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01414296
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath